Exploring patient preferences for colorectal cancer screening options
Understanding Patient Preference on Colorectal Cancer Screening Options
This study is trying to find out if a blood test for colorectal cancer screening can help people aged 45-75 who haven’t gotten screened before to feel more comfortable and willing to get tested.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 900 (estimated) |
| Ages | 45 Years to 75 Years |
| Sex | All |
| Sponsor | Milton S. Hershey Medical Center Academic / other |
| Locations | 1 site (Hershey, Pennsylvania) |
| Trial ID | NCT06444542 on ClinicalTrials.gov |
What this trial studies
This observational study aims to understand the barriers to colorectal cancer screening among underserved populations and evaluate the effectiveness of a blood-based screening option. By focusing on patients aged 45-75 who have previously failed or refused screening, the study seeks to improve compliance with recommended screening methods. The research will be conducted at partner Federally Qualified Health Centers (FQHCs) and will involve collecting blood samples to assess patient preferences and experiences. The ultimate goal is to enhance early detection of colorectal cancer and reduce mortality rates in high-risk groups.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 45-75 who are at average risk for colorectal cancer and have previously refused or failed to complete a screening test.
Not a fit: Patients with a family history of colorectal cancer or known hereditary gastrointestinal cancer syndromes will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to increased compliance with colorectal cancer screening, ultimately improving early detection and patient outcomes.
How similar studies have performed: Other studies have shown success in improving screening compliance through patient-centered approaches, making this a promising area of research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: To be enrolled in this study, participants must meet all the following criteria: 1. Between 45-75 years of age 2. Language Proficiency: participants must be fluent in English or Spanish 3. Have an average risk for colorectal cancer 4. Be a patient at one of our partner FQHCs 5. Received a screening order (either using a stool-based test or colonoscopy) six months ago and failed or refused to complete the screening test 6. Able and willing to provide a blood sample per protocol Exclusion Criteria: Participants will be excluded from enrolling in the study if they meet any of the following: 1. Family history * One first-degree relative diagnosed with CRC or advanced adenoma at age \<60 years * Two first-degree relatives diagnosed with CRC or advanced adenoma at any age * Known hereditary gastrointestinal cancer syndromes, such as Lynch Syndrome or Familial Adenomatous and Polyposis (FAP) 2. Personal History * Participants who do not speak either Spanish or English * History of CRC or adenoma * History of cancers * History of inflammatory bowel disease, including chronic ulcerative colitis and Crohn's disease * Have a recorded up to date CRC screening * Blood product transfusion in the past 120 days * A medical condition which, in the opinion of the patient's health provider, should preclude enrollment in the study
Where this trial is running
Hershey, Pennsylvania
- Penn State College of Medicine — Hershey, Pennsylvania, United States (Recruiting)
Study contacts
- Principal investigator: Karen E. Kim, MD — Penn State College of Medicine
- Study coordinator: Paula Lozano, PhD
- Email: plozanomesa@pennstatehealth.psu.edu
- Phone: 312-535-3750
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.